Core Insights - Aptose Biosciences Inc. has entered into a Cooperative Research and Development Agreement with the National Cancer Institute to develop tuspetinib for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [1][3] - The myeloMATCH trials aim to expedite the development of tailored drug combinations for newly diagnosed AML and MDS patients [2][3] - Tuspetinib is being developed as part of a triple drug combination therapy for newly diagnosed AML patients unfit for chemotherapy, with plans to initiate dosing soon [4][5] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5] - The lead compound, tuspetinib, is an oral kinase inhibitor showing promise as both a monotherapy and in combination therapies for relapsed or refractory AML [5] Clinical Development - The myeloMATCH trials, funded by the NCI, were launched on May 16, 2024, to provide tailored treatments for aggressive blood cancers [2] - Tuspetinib has demonstrated broad activity and a favorable safety profile in previous trials, making it a suitable candidate for combination therapies [4] - The Phase 1/2 TUSCANY study protocol for the TUS+VEN+AZA combination has been submitted and is expected to commence in the fourth quarter of 2024 [4][5]
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials